Previous 10 | Next 10 |
The FDA approves Merck KGaA ( OTCPK:MKGAY ) unit EMD Serono's Mavenclad (cladribine) tablets for the treatment of relapsing forms of multiple sclerosis (MS). More news on: Merck KGaA ADR, Celgene Corporation, Roche Holding AG, Healthcare stocks news, Read more ...
The FDA approves Novartis' (NYSE: NVS ) Mayzent (siponimod) for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome (defined as a first episode of neurologic symptoms that lasts at least 24 hours and is caused by inflammation or demyelinatio...
Adamas Pharmaceuticals ( ADMS ), recently announced their Q4/2018 earnings report revealing another beat on revenue and EPS. The company publicized GOCOVRI net sales of roughly $13.3M for Q4 of 2018 (Figure 3), with approximately 5,730 prescriptions ( 4,740 in Q3 ) sold. Adamas was able to...
Gainers: Document Security Systems (NYSEMKT: DSS ) +57% . Cool Holdings (NASDAQ: AWSM ) +38% . Fuwei Films (NASDAQ: FFHL ) +30% . China Rapid Finance (NYSE: XRF ) +23% . Ctrip.com International (NASDAQ: CTRP ) +21% . Aqua Metals (NASDAQ: AQMS ) +18% . BioHiTech Global (NASDAQ: ...
Atlas Financial Holdings (NASDAQ: AFH ) -49% on Q4 earnings . More news on: Atlas Financial Holdings, Adamas Pharmaceuticals, Inc., China Finance Online Co. Limited, Stocks on the move, Read more ...
Adamas Pharmaceuticals (NASDAQ: ADMS ) slumps 29% premarket on light volume on the heels of its Q4 report that appeared to disappoint investors despite meeting preannounced Q4 results released in early January. Highlights: More news on: Adamas Pharmaceuticals, Inc., Healthc...
Adamas Pharmaceuticals, Inc. (ADMS) Q4 2018 Earnings Conference Call March 4, 2019 4:30 p.m. ET Company Participants Greg Went - Chairman and CEO Alf Merriweather - CFO Rajiv Patni - Chief Medical Officer Conference Call Participants David Amsellem - Piper Jaffray Tim Lug...
Adamas Pharma (NASDAQ: ADMS ): Q4 GAAP EPS of -$1.06 beats by $0.32 . More news on: Adamas Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
EMERYVILLE, Calif., March 04, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today reported recent achievements and financial results for the fourth quarter and full-year ended December 31, 2018, along with key priorities for 2019. “We are excited ...
EMERYVILLE, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today announced that Gregory T. Went, Ph.D., the Company’s Founder, C...
News, Short Squeeze, Breakout and More Instantly...
Adamas Pharmaceuticals Inc. Company Name:
ADMS Stock Symbol:
NASDAQ Market:
Adamas Pharmaceuticals Inc. Website:
Supernus Pharmaceuticals (NASDAQ: SUPN) recently announced that it's acquiring Adamas Pharmaceuticals (NASDAQ: ADMS) . In this Motley Fool Live video recorded on Oct. 13 , Motley Fool contributors Keith Speights and Brian Orelli discuss why Supernus' planned acq...
FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Adamas Pharmaceuticals, Inc. Announces Definitive Agreement to be Acquired by Supernus Pharmaceuticals, Inc” Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) surged ove...
Supernus Pharmaceuticals Inc ( NASDAQ: SUPN ) recently announced that it had entered a definitive contract to acquire Adamas Pharmaceuticals ( NASDAQ: ADMS ). Supernus is to purchase this company a tender offer that was worth about $8.10 per share. The aggregate was roug...